File Name: Eurofins Fact sheet March 2012 EDR: 1-C-IR-EXE-01124131 Last modified on: 20/04/2012 Last modified by: Sylvain Besson Page 1 of 1

Our Vision: To be the World Leader in the bioanalytical testing market

Our Mission: To contribute to global health and safety by providing our customers with high quality laboratory and advisory services whilst creating opportunities for our employees and generating sustainable shareholder value

Our Values: Achievement of our Mission is based on Eurofins "Core Values", which commit us to Customer focus, Quality, Competence & Team Spirit and Integrity

Revenues in €m CAGR 14%

2007 2008 2009 2010 2011

Clean EBITDA in €m CAGR 21%

2007 2008 2009 2010 2011

Eurofins shares are listed on NYSE Euronext Paris (since IPO in October 1997) ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP Indices: SBF120, Next 150, Next Biotech, SRD, Compartment B Share price performance as of 19 Apr. 2012 (86.0 €) vs. IPO (10/1997) +4,601% Contact Pamela Antay, Investor Relations ir@eurofins.com Florian Heupel, Group Marketing info@eurofins.com Please refer to our on-line group directory for laboratory contact information http://www.eurofins.com/media/807166/group%20directory%20-%202010%20w%20link.pdf Addresses Chaussée de Malines 455 B- 1950 Kraainem (Brussels) – Belgium Tel +32 2 766 1620 10A, Rue Henri M. Schnadt, L-2530 Luxembourg – Luxembourg Tel + 35 2 261 85 31

EUROFINS FACT SHEET Company Overview Eurofins Scientific is an international life sciences company which provides a unique range of analytical testing services to clients across multiple industries. The Group is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services, and one of the global market leaders in agroscience, genomics and central laboratory services.

Short History Eurofins Scientific was founded in 1987 with 10 employees to market the SNIF-NMR technology, a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.

Today the Eurofins Group is a leading provider of analytical services with: • an international network of over 160 laboratories across 32 countries in

Europe, the USA, Asia and South America • over 12,000 staff • a portfolio of over 100,000 reliable analytical methods • more than 80 million assays performed each year to establish the safety,

identity, composition, authenticity, origin, traceability, and purity of biological substances and products.

Eurofins is one of the fastest growing companies in Europe: since its IPO on the French stock exchange in 1997, Eurofins’ sales have increased by about 40% each year (in compound average) to over US$ 1bn revenues in 2011.

Between the Initial Public Offering on 24 October 1997 and 19 April 2012, Eurofins’ share price has multiplied by 47x, an annual average increase of 29% (against 1x and 1% respectively for the CAC 40 index over the same period).

Recent Developments In 2011, with 22% revenue growth and 124% net proft increase, Eurofins started seeing the benefits from its simultaneous five-year intense investment program, and two-year reorganization program, both of which were concluded on schedule in 2010. The results of these initiatives have been reflected in an increased efficiency across the Group, and higher shares in most of the markets where the Group operates. Most importantly, these achievements have led to superior capabilities to service its clients, and higher profitability. Eurofins boasts a very modern, streamlined network of laboratories uniquely capable of providing high quality analyses at a reasonable cost.

Investments in start ups in 15 new countries, along with focused acquisitions, have substantially increased the range of Eurofins’ offerings in its customers’ key markets around the world. The Group’s 5 wholly owned laboratories in China and Hong Kong, as well as facilities in India and Japan in food, pharma and product testing operate to western standards and regulations. More sites are being planned in China and the rest of Asia. Overall, the new laboratories started up by Eurofins during the last five years in India, China, Brazil, Singapore, Eastern Europe, in particular should start contributing meaningfully to the Group’s overall growth from 2012 onwards.

Over the years, Eurofins has developed many new analytical testing methods and has participated in, or led several R&D projects to find better ways to analyse food, the environment and pharmaceuticals. Drawing on its world-class Competence Centres and its expertise, Eurofins is driving growth from its market-leading portfolio of tests, outsourcing agreements and through cross-selling opportunities across its world-wide laboratory network.

Consistent with its goal of securing the leading global position in its core competence areas, in April 2011, Eurofins acquired Lancaster Laboratories, the leading provider of pharmaceutical products testing and one of the largest environmental testing laboratories in North America.

Future Plans Eurofins is committed to supporting its clients’ objectives of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate. Eurofins intends to continue to develop and acquire the most comprehensive range of state-of-the-art analytical technologies as well as expand its geographical reach in order to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

69

91 92 111

147

829

497

633 640

896

2011*

* Pro- forma

680